In a new study, scientists have uncovered a powerful new use for abnormal cannabinoid (AbnCBD) derivatives.
These unique compounds, distinct from traditional cannabinoids, have shown remarkable effectiveness in combating drug-resistant Candida species, notes the study’s researchers. Published in Pharmacological Research, the study reveals how these derivatives not only inhibit fungal growth but also disrupt biofilm formation, offering a promising new approach to battling antifungal resistance.
The research was conducted by scientists from the University of Jerusalem, Ariel University, and The Hebrew University of Jerusalem. Their work focused on abnormal cannabinoids, a class of synthetic lipid compounds that, unlike traditional cannabinoids, do not interact with CB1 and CB2 receptors. Previous studies highlighted the cardioprotective and anti-inflammatory properties of one compound in particular, comp 3, as well as its antimicrobial potential against methicillin-resistant Staphylococcus aureus (MRSA).
Continue reading